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BACKGROUND: The preventive role of non-steroid anti-inflammatory drugs (NSAIDs) and aspirin, in particular, on colorectal cancer is
well established. More recently, it has been suggested that aspirin may also have a therapeutic role. Aim of the present observational
population-based study was to assess the therapeutic effect on overall survival of aspirin/NSAIDs as adjuvant treatment used after the
diagnosis of colorectal cancer patients.
METHODS: Data concerning prescriptions were obtained from PHARMO record linkage systems and all patients diagnosed with
colorectal cancer (1998–2007) were selected from the Eindhoven Cancer Registry (population-based cancer registry). Aspirin/
NSAID use was classified as none, prediagnosis and postdiagnosis and only postdiagnosis. Patients were defined as non-user of
aspirin/NSAIDs from the date of diagnosis of the colorectal cancer to the date of first use of aspirin or NSAIDs and user from first use
to the end of follow-up. Poisson regression was performed with user status as time-varying exposure.
RESULTS: In total, 1176 (26%) patients were non-users, 2086 (47%) were prediagnosis and postdiagnosis users and 1219 (27%) were
only postdiagnosis users (total n¼ 4481). Compared with non-users, a survival gain was observed for aspirin users; the adjusted rate
ratio (RR) was 0.77 (95% confidence interval (CI) 0.63–0.95; P¼ 0.015). Stratified for colon and rectal, the survival gain was only
present in colon cancer (adjusted RR 0.65 (95%CI 0.50–0.84; P¼ 0.001)). For frequent users survival gain was larger (adjusted RR
0.61 (95%CI 0.46–0.81; P¼ 0.001). In rectal cancer, aspirin use was not associated with survival (adjusted RR 1.10 (95%CI 0.79–1.54;
P¼ 0.6). The NSAIDs use was associated with decreased survival (adjusted RR 1.93 (95%CI 1.70–2.20; Po0.001).
CONCLUSION: Aspirin use initiated or continued after diagnosis of colon cancer is associated with a lower risk of overall mortality.
These findings strongly support initiation of a placebo-controlled trial that investigates the role of aspirin as adjuvant treatment in
colon cancer patients.
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With 1 000 000 new cases and 600 000 deaths worldwide each year,
colorectal cancer is one of the most common cancers in developed
countries (Weitz et al, 2005). Aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs) are potentially effective chemo-
preventive agents for a number of cancers, but most clearly for
colorectal cancer. Several randomised and observational studies
have unequivocally shown that regular use of aspirin or NSAIDs
reduces the risk of a colorectal malignancy (Giovannucci et al,
1994, 1995; Baron et al, 2003; Sandler et al, 2003; Chan et al, 2007;
Rothwell et al, 2010, 2011). In a recent study by Chan et al (2009)
reported a risk reduction of 21% for regular aspirin users as
compared with non-users for overall mortality. In their study,
patients diagnosed with stage I–III colorectal cancer were included;
use of aspirin was assessed using a biannual questionnaire among
the cohort of health professionals. The effect was larger when
aspirin was initiated after the diagnosis of colorectal cancer.
However, widespread use of NSAIDs or aspirin for colorectal
cancer prevention is not advised as mentioned in a recent
international consensus statement, where it was concluded that
the data on the risk-benefit profile for cancer prevention are
insufficient and as such no definitive recommendation could be
made (Cuzick et al, 2009).
Aspirin inhibits cyclooxygenase (COX), induces apoptosis
through p38 activation (Schwenger et al, 1997) and inhibits
nuclear factor-kappaB. All of these mechanisms have been
hypothesised to inhibit adenomatous polyp formation. Experi-
mental data showed that COX-2 expression is associated with
angiogenesis, tumour invasiveness and metastatic potential of
colon cancer cells and that these traits can be reversed by selective
COX-2 inhibitors (Tsujii et al, 1997, 1998; Chen et al, 2001).
Nevertheless, it is not clear if aspirin use can influence the
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prognosis of patients already diagnosed with colorectal cancer. In
animal models, aspirin or other NSAIDs, with activity against
COX-2, have shown to inhibit tumour growth and metastases as
well as prolonged survival (Tomozawa et al, 1999; Williams et al,
2001; Yao et al, 2003, 2005). A recent study in breast cancer
patients (Nurses’ Health Study) showed a decreased risk of distant
recurrence and breast cancer death in patients who used aspirin
(Holmes et al, 2010). For colorectal cancer (stage I–III) patients
who regularly used aspirin after their colorectal cancer had an
increased survival (hazard ratio 0.71) (Chan et al, 2009).
The aim of this study was to assess the therapeutic effect
of aspirin or non-aspirin NSAIDs use after the diagnosis of
colorectal cancer on overall survival. A large, patient-centric data
network including multiple, linked databases designed for safety
and outcomes research in the Netherlands were linked to data
from a regional cancer registry (van Herk-Sukel et al, 2010). The
new combined database offers a unique opportunity to assess
survival according to aspirin or other non-aspirin NSAIDs use
before and after the diagnosis of colorectal cancer.
PATIENTS AND METHODS
Patients
The central patient database of the PHARMO record linkage
system is linked to more than 10 different databases and has
recently been linked to the database from the Eindhoven Cancer
Registry (ECR). Detailed information concerning this new
database is described elsewhere (van Herk-Sukel et al, 2010).
From the ECR, all patients diagnosed with colorectal cancer
between 1998 and 2007 were selected. This southern region of the
Netherlands is served by 10 hospitals each serving a population
between 150 000 and 250 000 people. All patients were included,
there were no exclusion criteria. Of these patients prescriptions of
aspirin and NSAIDs were selected from the PHARMO databases
(see Supplementary Table 1). The largest proportion of patients
used aspirin 80mg per day (95%), 5% of the patients used aspirin
30mg per day. The date of dispensing and date of diagnosis were
compared to assess whether the aspirin/NSAIDs were prescribed
before and/or after diagnosis. Non-users were defined as patients
who never used prescribed aspirin/NSAIDs. Patients, who ever
used a prescribed aspirin or NSAID, were classified as user if they
had a prescription for aspirin or NSAIDs for at least 14 days,
patients who had a prescription for less than 14 days were defined
as non-users (3.5% of all patients). Frequent users were defined as
patients that had a least three prescriptions. Date of diagnosis was
compared to the date of prescription; users were subsequently
classified as prediagnosis and postdiagnosis use and solely
prediagnosis or solely postdiagnosis use. Low-dose aspirin
(80mg) is always on prescription in the Netherlands, so
misclassification is lower with aspirin than with NSAIDs.
Statistical analysis
Definition of user and follow-up time As information concerning
the prescriptions in hospital was unknown, follow-up time for the
general analysis was defined as 30 days from diagnosis (T0) of
colorectal cancer to the last contact date or time of death (patients
who died within 30 days were excluded from the survival analysis,
2.4% for colon cancer and 1.0% for rectal cancer). If the follow-up
would have started at the date of diagnosis, immortal time bias
would have been introduced, as our analysis rely on drug
dispensing from pharmacies that requires a patient to be
discharged from the hospital. Time to first dispensing was,
consequently, calculated as the time from 30 days after diagnosis
to the date of the first prescription.
Frequent users were defined as patients who had three or more
consecutive refills of aspirin (within 9 months). As the prescribed
refills are for 3 months each, follow-up for analyses with frequent
user as exposure started 9 months after T0 until to the last contact
or time of death. Patients who had less than three refills were
classified as non-users. Additionally, we performed a sensitivity
analysis, where patients that initiated the frequent use of aspirin
with a longer time interval after the diagnosis (3 years) were coded
as non-users.
Prediagnosis and postdiagnosis users were defined as those
patients that initiated their use before diagnosis and continued to
use until at least 3 months after diagnosis. Consequently, the
follow-up for this group started at 3 months after T0 and ended at
the date of last contact of time of death.
Survival analysis Vital status was identified through linkage of
cancer registry data with the municipal population registries,
which record information on their inhabitant’s vital status. For the
survival analysis with time-dependent exposure, patients were
defined as non-users from T0 to the date of first use of aspirin or
NSAIDs and user from first use to the end of follow-up period to
prevent immortal time bias (Suissa, 2008). Poisson regression
models were used to model the effect of aspirin/NSAID use on
overall survival, where death from any cause was coded as event.
For the analysis of prediagnosis and postdiagnosis users, a Poisson
regression survival model was used without the time-varying
covariate. Patients with solely prediagnosis use were analysed
separately and defined as user or non-user prediagnosis; analyses
were performed using a multivariable Cox proportional hazard
model. Multivariable models were build to adjust for sex, age,
comorbidity, year of incidence, grade, stage, surgery, adjuvant
chemotherapy for colon cancer patients and preoperative radio-
therapy for rectal cancer patients. We had information concerning
the presence or absence of the next comorbidities: lung diseases,
cardiovascular diseases, GI tract, urinary tract, diabetes, nervous
system, diseases of the muscles and joints and a group of other
comorbidities. All comorbidities were grouped in no comorbidities
or X1 comorbidity for the analysis.
Analyses were stratified for colon and rectal cancer patients and
for aspirin or NSAID use vs non-users; a small percentage of
patients received prescriptions for both (11%), they were included
in the category of the medication most prescribed.
RESULTS
In total, 4481 patients were diagnosed with colorectal cancer in the
period 1998–2007 and included in the present study. Table 1 shows
the characteristics of this population. Almost two-third of the
patients were diagnosed with colon cancer (n¼ 2793; 62%) and
about one third with rectal cancer (n¼ 1688; 38%). Median age at
diagnosis was 69 years (range 22–99). A large proportion of the
patients underwent surgery (91%). One in four patients (26%) had
never used any prescribed aspirin/NSAID (non-users), 47% before
and after the diagnosis of colorectal cancer and 27% only
postdiagnosis.
Table 2 shows the association of tumour characteristics with
aspirin/NSAIDs use, stratified for colon and rectal cancer patients.
Patients with postdiagnosis use (with or without prediagnosis use)
were more often diagnosed with stage I colon cancer and less often
with stage IV disease (Po0.001). For rectal cancer, the associations
were less prominent for stage (P¼ 0.1).
Survival analysis with time-varying covariate
Table 3 shows the univariate survival analysis of patient and
tumour characteristics. Age (Po0.001), comorbidity (Po0.001),
year (Po0.001 for colon and P¼ 0.005 for rectal), grade (Po0.001
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for colon and P¼ 0.001 for rectal), stage (Po0.001) and surgery
(Po0.001) were associated with survival in colon and rectal cancer
patients. Sex was not associated with survival (P¼ 0.09 for colon
and P¼ 0.3 for rectal cancer). Chemotherapy for colon cancer
patients was not associated with survival (P¼ 0.5); radiotherapy
for rectal cancer patients was, on the contrary, associated with
survival (P¼ 0.004).
Table 4 shows the results comparing mortality between users of
aspirin postdiagnosis vs non-user. For all patients with colorectal
cancer, aspirin use after diagnosis was associated with a significant
reduction of the overall mortality rate ratio (RR) 0.75 (95%
confidence interval (CI) 0.62–0.92; P¼ 0.005). Adjusted for sex,
age, comorbidity, year of incidence, grade, stage and treatment, the
multivariable RR for aspirin users compared with non-users was
0.77 (95%CI 0.63–0.95; P¼ 0.015). Frequent use of aspirin
postdiagnosis was also associated with a improved survival with
a multivariable RR of 0.70 (95%CI 0.57–0.88; P¼ 0.002). Multi-
variable analysis of the prediagnosis and postdiagnosis users also
showed a significant association with survival (RR 0.88 (95%CI
0.83–0.94; Po0.001)).
Stratified analysis for colon and rectal cancer showed that the
survival gain was only present in patients with colon cancer. A
significant reduction of mortality was shown in aspirin users
(independent of the frequency) as compared with non-users with a
RR of 0.62 (95%CI 0.46–0.80; Po0.001). After adjusting for
potential confounders, the survival gain was still present with a RR
of 0.65 (95%CI 0.50–0.84; P¼ 0.001) for users of aspirin as
compared with non-users. For frequent users of aspirin the
survival gain was somewhat larger with an adjusted RR of 0.61
(95%CI 0.46–0.81; P¼ 0.001) for users as compared with non-
users. A sensitivity analysis, where patients that initiated frequent
aspirin use after 3 years were coded as non-users, showed an
adjusted RR of 0.60 (95%CI 0.44–0.81; P¼ 0.001). Stratified
analyses for chemotherapy or no chemotherapy showed a
significant survival gain in patients who received no chemotherapy
(adjusted RR 0.67 (95%CI 0.51–0.89; P¼ 0.006), however, no
Table 1 Characteristics of the cohort
Variable Number Percentage
Sex
Male 2534 57
Female 1947 43
Localisation
Colon 2793 62
Rectal 1688 38
Age (years)
o65 1745 39
65–74 1407 31
X75 1329 30
Grade
I 502 11
II 2580 58
III 682 15
Unknown 717 16
Stage
I 978 22
II 1419 32
III 1163 26
IV 722 16
Unknown 199 4
Surgery
No 400 9
Yes 4081 91
Postoperative chemotherapy (colon)
No 1862 72
Yes 713 28
Radiotherapy (rectal)
No 623 37
Yes 1065 63
Prescribed aspirin or NSAIDs
None 1176 26
Prediagnosis and postdiagnosis 2086 47
Only postdiagnosis 1219 27
Postdiagnosis
Aspirin 275 23
NSAIDs 944 77
Abbreviation: NSAID¼ non-steroid anti-inflammatory drug.
Table 2 Aspirin or NSAIDs use and patient and tumour characteristics
Aspirin or NSAIDs use
None
Prediagnosis
and
postdiagnosis
Only
postdiagnosis P-value
Colon cancer
Sex
Male 389 (52.0) 707 (53.8) 383 (52.5) 0.02
Female 359 (48.0) 608 (46.2) 347 (47.5)
Age
o65 years 237 (31.7) 451 (34.3) 292 (40.0) o0.001
65–74 years 215 (28.7) 421 (32.0) 246 (33.7)
X75 years 296 (39.6) 443 (33.7) 192 (26.3)
Grade
I 87 (11.6) 176 (13.4) 96 (13.2) o0.001
II 436 (58.3) 772 (58.7) 443 (60.7)
III 127 (17.0) 229 (17.4) 116 (15.9)
Unknown 98 (13.1) 138 (10.5) 75 (10.3)
Stage
I 111 (14.8) 225 (17.1) 131 (17.9) o0.001
II 274 (36.6) 476 (36.2) 271 (37.1)
III 170 (22.7) 359 (27.3) 201 (27.5)
IV 150 (20.1) 208 (15.8) 109 (14.9)
Unknown 43 (5.7) 47 (3.6) 18 (2.5)
Rectal cancer
Sex
Male 284 (66.4) 460 (59.7) 311 (63.6) 0.1
Female 144 (33.6) 311 (40.3) 178 (36.4)
Age
o65 years 170 (39.7) 334 (43.3) 261 (53.4) o0.001
65–74 years 125 (29.2) 252 (32.7) 148 (30.3)
X75 years 133 (31.1) 185 (23.0) 80 (16.3)
Grade
I 37 (8.6) 72 (9.3) 34 (6.9) 0.002
II 240 (56.1) 401 (52.0) 288 (58.9)
III 46 (10.8) 87 (11.3) 77 (15.8)
Unknown 105 (24.5) 211 (27.4) 90 (18.4)
Stage
I 112 (26.2) 252 (32.7) 147 (30.1) 0.1
II 106 (24.8) 176 (22.8) 116 (23.7)
III 111 (25.9) 185 (24.0) 137 (28.0)
IV 70 (16.4) 117 (15.2) 68 (13.9)
Unknown 29 (6.8) 41 (5.3) 21 (4.3)
Abbreviation: NSAID¼ non-steroid anti-inflammatory drug.
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significant survival gain in those patients that received chemother-
apy (adjusted RR 0.51 (95%CI 0.23–1.13; P¼ 0.1). For elderly
patients (75 and older) who received no chemotherapy, the
survival gain was especially large (adjusted RR 0.52 (95%CI
0.35–0.78; P¼ 0.001)). The survival gain for patients that used
aspirin prediagnosis and postdiagnosis was not significant in
univariate analysis (RR 0.92 (95%CI 0.78–1.08; P¼ 0.3)), however,
adjusted for potential confounders the overall mortality was
significantly reduced in users (RR 0.89 (95%CI 0.82–0.96;
P¼ 0.003)).
In rectal cancer patients, no significant survival gain for aspirin
users as compared with non-users was observed. In all patients
that used aspirin, the adjusted RR was 1.10 (95%CI 0.79–1.54;
P¼ 0.6). For frequent users of aspirin with rectal cancer there was
also no survival gain (adjusted RR 0.94 (95%CI 0.65–1.34; P¼ 0.7).
In multivariable analysis there was a significant survival gain for
users prediagnosis and postdiagnosis (RR 0.87 (95%CI 0.78–0.97;
P¼ 0.01)).
Table 5 shows the results of the time-dependent survival analysis
for the NSAIDs. In all colorectal patients, users of NSAIDs had a
decreased survival as compared with non-users; the adjusted RR
was 1.93 (95%CI 1.70–2.20; Po0.001). Stratified for colon and
rectal cancer, the same pattern was shown in both patient groups
with an adjusted RR for colon cancer of 1.79 (95%CI 1.52–2.11;
Po0.001) and 2.27 (95%CI 1.84–2.82; Po0.001) for rectal cancer
in users as compared to non-users.
Figure 1 shows the overall survival curve for aspirin users in
colon cancer patients.
Supplementary Table 1 shows the analysis of solely prediagnosis
users. For patients with colon cancer, prediagnosis users had a
significantly worse survival than patients without prescribed
aspirin or NSAIDs (adjusted HR NSAIDs 1.3 (95%CI 1.1–1.5;
P¼ 0.007) and aspirin HR 1.5 (95%CI 1.2–1.8; Po0.001)). For
prediagnosis users with rectal cancer there was no significant
association between prediagnosis use of NSAIDs and survival (HR
1.1 (95%CI 0.8–1.4; P¼ 0.7)), however, there was a significant
worse survival for patients who used prescribed aspirin prediag-
nosis (HR 1.4 (95%CI 1.0–2.0; P¼ 0.03)).
DISCUSSION
Aspirin may have an important role as a cancer treatment agent in
the adjuvant setting (Neugut, 2009). This is the largest observa-
tional study that assessed the value of ‘adjuvant’ use of aspirin/
NSAIDs. In this study, we observed that aspirin use initiated or
continued after the diagnosis of colon cancer was associated with a
markedly increased overall survival. The effect was present in
several subgroups and dependent on the frequency of prescription.
Our results add important new observations. First, using a time-
varying covariate in a survival model, we show for the first time the
therapeutic effect of aspirin in colon cancer patients. Second, owing
to the large number of patients, we were able to stratify for age.
Elderly patients that received no chemotherapy had the most benefit
of aspirin in terms of overall survival. Furthermore, the therapeutic
effect of aspirin was larger with increased number of prescriptions.
Third, the effect of overall survival was specific for aspirin. Use of
non-aspirin NSAIDs in our analysis showed the opposite effect.
These results are in line with other reports that investigated the
role of aspirin or NSAIDs in colorectal cancer therapy. The recent
study of Chan et al (2009) showed a similar risk reduction as
compared to our study; where the present study included more
patients and was no biased by recall. In another study by Coghill
et al (2011), regular NSAID use before the diagnosis of colorectal
cancer was associated with a significant lower colorectal cancer-
specific death rate. In that study aspirin use seem to be more
relevant than ibuprofen for survival. In our study, surprisingly, the
effect on overall survival was only present in colon cancer patients
Table 3 Univariate survival analysis of patient and tumour characteristics,
stratified by the type of cancer
Rate ratio (95%CI) P-value
Colon cancer
Sex
Male Reference 0.09
Female 0.85 (0.71–1.02)
Age
Continuous 1.06 (1.05–1.07) o0.001
Comorbidity
No Reference o0.001
Yes 1.41 (1.17–1.70)
Incidence year
Continuous 1.07 (1.04–1.11) o0.001
Grade
I Reference o0.001
II 0.87 (0.65–1.15)
III 1.33 (0.96–1.85)
Unknown 1.65 (1.17–2.32)
Stage
I Reference o0.001
II 1.26 (0.91–1.74)
III 1.76 (1.26–2.47)
IV 13.80 (10.07–18.91)
Unknown 6.30 (4.10–9.69)
Chemotherapy
No Reference 0.5
Yes 1.08 (0.86–1.34)
Surgery
No Reference o0.001
Yes 0.05 (0.04–0.06)
Rectal cancer
Sex
Male Reference 0.3
Female 1.14 (0.89–1.48)
Age
Continuous 1.08 (1.07–1.09) o0.001
Comorbidity
No Reference o0.001
Yes 1.94 (1.52–2.48)
Incidence year
Continuous 1.06 (1.02–1.11) 0.005
Grade
I Reference 0.001
II 1.41 (0.85–2.33)
III 2.59 (1.48–4.53)
Unknown 1.72 (1.00–2.97)
Stage
I Reference o0.001
II 2.01 (1.34–3.03)
III 1.85 (1.24–2.76)
IV 13.73 (9.33–20.20)
Unknown 9.66 (5.94–15.70)
Radiotherapy
No Reference 0.004
Yes 0.70 (0.55–0.89)
Surgery
No Reference o0.001
Yes 0.08 (0.06–0.10)
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that used aspirin. In rectal cancer patients and in patients using
non-aspirin NSAIDs, no effect on survival was seen. On the
contrary, non-aspirin NSAID use was associated with a worse
survival. We cannot rule out that ‘over the counter’ use of popular
pain medication, such as voltaren and ibuprofen, confounded
these results. However, low-dose aspirin is always on prescription
in the Netherlands and the risk of bias concerning ‘over the
counter use’ is neglectable. Interestingly, in our study, the
observed survival benefit was largest among patients that initiated
aspirin use after the diagnosis of colon cancer. In patients that
started aspirin before their colon cancer and continued thereafter,
the beneficial effect on overall survival was less profound. The
results of our study and others are also in line with the recent
observation that long-term use of aspirin in cardiovascular
prevention trials is associated with a reduction of death from
colorectal cancer that is even greater than the reduction in
incidence (Rothwell et al, 2010). An earlier study of patients with
stage III colon cancer enrolled in an adjuvant chemotherapy trial
showed that aspirin use was associated with a lower risk of disease
recurrence and death (Fuchs et al, 2005). In contrast to the studies
of Chan et al (2009) and Coghill et al (2011), patients who used
aspirin or NSAIDs solely before diagnosis had a worse survival
than non-users. Chan et al showed no association between aspirin
use before cancer diagnosis and overall mortality (HR 0.93; 95%CI
0.77–1.11); however, Coghill et al showed a significant association
between prediagnosis NSAID use and colorectal cancer-specific
survival (HR 0.79; 95%CI 0.65–0.97). In the present study, we
found a negative association between overall survival and
prediagnosis use, which could be associated with the overall worse
general health of these patients or could be biased by ‘over the
counter’ use of NSAIDs. This ‘over the counter’ use could also have
biased the negative association between survival and use of
NSAIDs postdiagnosis.
In the Netherlands low-dose aspirin was not prescribed for the
purpose of cancer prevention or treatment during the study
period. Therefore, it is highly likely that virtually all patients
Table 4 Time-dependent survival analysis (overall survival), stratified by colon or rectal cancer, for non-users and users of aspirin
User/
non-user
Patients
(n)
Person-
years Deaths Rate ratio P-value
Adjusted
rate ratioa P-value
Colorectal cancer
Aspirin postdiagnosisb Non-user 1176 5059 610 Reference 0.005 Reference 0.015
User aspirin 275 1258 114 0.75 (0.62–0.92) 0.77 (0.63–0.95)
Aspirin frequent users postdiagnosisb Non-user 1451 5172 628 Reference 0.001 Reference 0.002
Frequent user 234 1145 96 0.69 (0.56–0.86) 0.70 (0.57–0.88)
Aspirin prediagnosis and postdiagnosis Non-user 1309 5184 627 Reference 0.5 Reference o0.001
User 819 3303 383 0.96 (0.84–1.09) 0.88 (0.83–0.94)
Colon cancer
Aspirin postdiagnosisb Non-user 748 3112 397 Reference o0.001 Reference 0.001
User aspirin 172 823 65 0.62 (0.48–0.80) 0.65 (0.50–0.84)
Aspirin frequent users postdiagnosisb Non-user 772 3194 406 Reference o0.001 Reference 0.001
Frequent user 148 741 56 0.59 (0.45–0.79) 0.61 (0.46–0.81)
Aspirin prediagnosis and postdiagnosis Non-user 843 3261 407 Reference 0.3 Reference 0.003
User 533 2173 249 0.92 (0.78–1.08) 0.89 (0.82–0.96)
Rectal cancer
Aspirin postdiagnosisb Non-user 428 1947 213 Reference 0.9 Reference 0.6
User aspirin 103 435 49 1.03 (0.75–1.40) 1.10 (0.79–1.54)
Aspirin frequent users postdiagnosisb Non-user 445 1978 222 Reference 0.5 Reference 0.7
Frequent user 86 404 40 0.88 (0.63–1.23) 0.94 (0.65–1.34)
Aspirin prediagnosis and postdiagnosis Non-user 466 1923 220 Reference 0.7 Reference 0.01
User 286 1130 134 1.04 (0.84–1.28) 0.87 (0.78–0.97)
aAdjusted for sex, age, comorbidity, year of incidence, grade, stage, chemotherapy (colon cancer), radiotherapy (rectal cancer) and surgery (all variables with Po0.05 in univariate
analysis were entered in the multivariable analysis, together with sex and treatment). Median follow-up: 3.5 (0–12) years. bPostdiagnosis users are patients that used aspirin solely
postdiagnosis and not prediagnosis. The bold and italic entries indicate Po0.05.
Table 5 Time-dependent survival analysis (overall survival), stratified by colon or rectal cancer, for non-users and NSAIDs users
User/non-user Patients (n) Person-years Deaths
Rate
ratio P-value
Adjusted
Rate ratioa P-value
Colorectal cancer
NSAIDs postdiagnosisb Non-user 1176 6362 610 Reference o0.001 Reference o0.001
User NSAIDs 944 3556 440 1.29 (1.14–1.46) 1.93 (1.70–2.20)
Colon cancer
NSAIDs postdiagnosisb Non-user 748 3903 397 Reference 0.003 Reference o0.001
User NSAIDs 558 2049 263 1.26 (1.08–1.47) 1.79 (1.52–2.11)
Rectal cancer
NSAIDs postdiagnosisb Non-user 428 2458 213 Reference 0.003 Reference o0.001
User NSAIDs 386 1507 177 1.36 (1.11–1.65) 2.27 (1.84–2.82)
Abbreviation: NSAID¼ non-steroid anti-inflammatory drug. aAdjusted for sex, age, comorbidity, year of incidence, grade, stage, chemotherapy (colon cancer), radiotherapy
(rectal cancer) and surgery (all variables with Po0.05 in univariate analysis were entered in the multivariable analysis, together with sex and treatment). Median follow-up: 3.5
(0–12) years. bPostdiagnosis users are patients that used aspirin solely postdiagnosis and not prediagnosis.
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received aspirin to prevent morbidity and mortality from
cardiovascular disease. However, the effect of aspirin on overall
mortality in cardio-prevention trials is small and not significant in
a recent meta-analysis (HR 0.95 (95%CI 0.88–1.02; P¼ 0.1)
(Baigent et al, 2009). The survival gain in our analysis remained
present after further adjustment for comorbidity and after
excluding stage IV patients. Colon cancer patients who used
aspirin prediagnosis and postdiagnosis had less benefit of aspirin
than postdiagnosis users, which is biologically plausible consider-
ing that tumours that developed in prediagnosis users were not
prevented by aspirin use (Chan et al, 2009; Neugut, 2009).
However, the immortal time bias could have biased the results in
this specific subgroup, as patients that were on aspirin could not
have died in that period (Suissa, 2008).
The mechanism by which aspirin exerts its activity is not
completely understood. An inverse association between the
incidence of various cancers and the use of aspirin or other
NSAIDs has been supported by epidemiological studies, animal
models and plant studies (Elwood et al, 2009). The NSAID’s cancer
protective activity has been attributed to direct inhibition of the
COX family of enzymes involved in prostaglandin synthesis. The
COX-2 enzyme is strongly and rapidly induced in response to
mediators of inflammation, growth factors, cytokines and endo-
toxins; and its expression correlates with increased cell prolifera-
tion and tumour promotion (Herschman, 1996). Aspirin can
decrease the production of potentially neoplastic prostaglandins
arising from COX-2-mediated catalysis of arachidonic acid (Vane,
1971). However, aspirin has a much broader range of downstream
effectors, such as NF-KB, insulin-like growth factor I and many
others, as well as the inhibition of Wnt signalling and stem cell
growth possibly as the result of enhanced beta-catenin phosphory-
lation (Dihlmann et al, 2001, 2003; Wang et al, 2006).
Cancer is a heterogeneous disease encompassing differentiated
cell types but also less committed stem-like cells. Recent evidence
suggests that a subpopulation of tumour cells with distinct features
such as self-renewal and the ability to differentiate into multiple
lineages is responsible for tumour initiation, invasive growth and
possibly dissemination to distant organ sites. The acquired ability
of a cell to resist to apoptosis is a hallmark of almost all types of
cancer. Recently, it has been shown that IL-4 expression is
essential for the resistance to DNA damage-induced apoptosis of
colon cancer stem cells (CSCs) (Todaro et al, 2007). The CSCs are
also resistant to the cytotoxic effect of chemotherapy. It is plausible
that aspirin may not only act as a preventive agent in CRC onset by
modulating the Wnt pathway in CSCs but also as adjuvant
treatment by increasing CSC’s sensitivity to conventional che-
motherapy regimens.
This observational study may suffer from several forms of bias.
First, despite the biological plausibility of our results, confounding
by indication can be a problem. Most of the patients used the low-
dose aspirin for cardiovascular disease prevention. Theoretically,
the effect of aspirin in our cohort may be considered as a side
effect of the drug in these patients, and that makes observational
data more suitable for these analyses (Vandenbroucke, 2008).
Second, we have only data concerning the prescribed drugs, and do
not know the use of other aspirin or NSAIDs. However, by linkage
of two validated databases, our study does not suffer from recall
bias, which may exist if aspirin use is assessed by questionnaires.
Third, unfortunately we did not have any information concerning
COX-2 expression of the tumours, which seems to be associated
with recurrence and survival for colorectal cancer patients or
concerning the cancer-specific survival.
Our findings could have profound clinical implications. In this
study, we demonstrate the therapeutic effect of a well-tolerated
drug that cost mere pennies per day. Especially in the increasing
elderly population with colon cancer, many patients are considered
unfit for adjuvant chemotherapy. Age and comorbidity are the
strongest predictors of a medical oncologist not recommending
adjuvant chemotherapy (Keating et al, 2008). The demonstration
of the therapeutic anti-cancer effect of aspirin would be a major
clinical advance. However, the formal demonstration will still need
a placebo-controlled randomised trial, which will be initiated in
the Netherlands.
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